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the geRman nice oR the geRman nasty? an analysis of iqwig 
decisions and RequiRements foR an ‘added benefit'
Griffiths EA
PAREXEL, London, UK
Objectives: IQWiG (The Institute for Quality and Economic Efficiency in Health 
Care or Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen) 
assesses the added benefit of new medicines in Germany, with stringent evidence 
requirements. To inform future submissions, all IQWiG decisions from January 2011 
to May 2015 were assessed, and the effect of the clinical evidence base on the sub-
mission outcome was examined. MethOds: All completed IQWiG drug appraisals 
from January 2011 to May 2015 were included in the analysis. Multiple-technology 
appraisals, non-drug intervention appraisals, and incomplete assessments were 
excluded. The recommendation (‘added benefit’ or ‘no added benefit’), indica-
tion, underlying rationale, and evidence base presented were extracted. Results: 
Between 2011 and May 2015, IQWiG published 132 drug appraisals, including 30 
resubmission/addendums. 50/132 (38%) of the appraisals were deemed to offer an 
added benefit (14% in all subpopulations; 24% in some subpopulations only), while 
82/132 (62%) of appraisals received a ‘no added benefit’ decision. Only 2/34 (6%) 
of appraisals lacking head-to-head evidence received an ‘added benefit’ decision, 
compared with 47/84 (56%) of appraisals reporting head-to-head evidence against an 
appropriate comparator and 0/14 (0%) of appraisals reporting head-to-head evidence 
against an inappropriate comparator. Oncologics, infectious disease drugs, and car-
diovascular drugs had the highest proportion of submissions receiving an ‘added 
benefit’ decision. Over time, the proportion of submissions receiving a ‘no added 
benefit decision’ has increased, from 50% (4/8) in 2011, to 52% (12/23) in 2012, 65% 
(26/40) in 2013, 64% (27/42) in 2014, and 68% (13/19) so far in 2015. cOnclusiOns: 
Over half of drugs appraised by IQWiG since 2011 have been given ‘no added benefit’ 
status, and direct evidence against an appropriate comparator remains a priority for 
a favourable decision. In contrast, NICE has rejected just 15% of technology appraisal 
submissions since its inception in 2000, highlighting the differences between the 
two agencies.
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do evidence Review gRouPs bias nice decisions?
Versoza L, Jaksa A, Liden D, Ho Y
Context Matters, New York, NY, USA
Objectives: NICE designates one of nine independent academic centers as an 
Evidence Review Group(ERG) or Assessment Group(AG) to systematically review 
the clinical efficacy and cost-effectiveness of a product or products based on 
a manufacturer-submitted dossier or on published evidence. The ERG/AG’s 
report is integral to NICE’s decision-making process. This presentation explores 
whether NICE appraisals—particularly final reimbursement decisions—vary based 
on which ERG/AG was consulted. This evaluation is important from policy and 
industry perspectives as it can demonstrate whether NICE’s choice of ERG/AG 
is a potential source of bias in the technology appraisal process. To explore this 
topic, we examine clinical and economic factors within NICE appraisals influ-
enced by different ERG/AGs. MethOds: Reimbursement decision, therapeutic 
area (TA), manufacturer base-case ICER, NICE’s most plausible ICER, and clini-
cal and economic rationales for decision were extracted from NICE technology 
appraisal guidances from 2003-present. These factors were compared across ERG/
AGs. Results: NICE reviewed a total of 305 indications, with 72% resulting in posi-
tive decisions. Eleven different ERG/AGs were commissioned. There was no differ-
ence in rates of positive decisions between the different ERG/AGs (p= .69) though 
there was a wide range (mean = 72% [71% - 89%]). BMJ had the lowest rate of posi-
tive decisions and Warwick Evidence had the highest. There were differences in 
the number of oncology drugs reviewed by ERG/AG: Kleijnen Systematic Reviews 
assessed the most (60%) while Aberdeen HTA Group evaluated the fewest (4.6%). 
The presentation will show rates of positive decisions and clinical and economic 
rationales for decision by ERG/AG while controlling for TA. The presentation will 
also compare the most plausible ICERs and manufacturer base-case ICERs by ERG/
AG. cOnclusiOns: This study is the first systematic investigation of the influence 
of ERG/AGs on NICE reimbursement decisions. We will examine the components 
of the clinical and economic assessments as well as reimbursement decisions by 
ERG/AG.
abstRacts
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the canceR dRugs fund in england – undeRmining nice oR efficient 
and good value foR money?
Harries M, Marshall JD, Stewart D
MAP BioPharma Limited, Cambridge, UK
Objectives: Since its inception in 2010, the National Cancer Drugs Fund (NCDF) 
has become an important market access route for cancer medicines in England and 
became fully established in April 2011. The objective of this analysis was to review 
the decisions made by the NCDF to date, in the context of NICE decisions, and iden-
tify how recent and proposed changes to the NCDF might impact on future decisions 
and the evaluation process for oncology products. MethOds: The NCDF list was 
analysed and compared against those appraised by NICE to obtain the percentage 
that are rejected by NICE as well as those that are never assessed by NICE. Trends 
across indications and the number of drugs represented on the NCDF were also 
analysed. Policy documents and consultations on proposed process changes to the 
NCDF were also reviewed. Results: As of May 2015 there are 38 drugs covering 67 
indications approved on the NCDF list, many of which have been rejected by NICE. 
Recently implemented and proposed changes such as a change to the definition 
of rarity when scoring the median drug cost per patient, and the appeal process, 
could have significant implications for pharmaceutical companies and patients on 
gaining reimbursement for oncology products. cOnclusiOns: The existence of 
the NCDF suggests that NHS England sees cancer as having more value than other 
diseases. Evidence suggests that the NCDF has been a success in providing access 
to medicines for patients but could be seen as undermining the NICE evaluation 
process. Recent changes in the NCDF appear to try and close this gap.
ag4
inflation, inflexibility and iRRelevance – the need foR inflation to 
be accounted foR in iceR thResholds
Macaulay R, Udechuku A
PAREXEL, London, UK
Objectives: Many obligate cost-utility Health Technology Assessment (HTA) bod-
ies formally or informally reference incremental cost-effectiveness ratio (ICER) 
thresholds as key criteria that new medicines must satisfy to receive reimburse-
ment approval. One such body, the National Institute of Health and Care Excellence 
(NICE), in 2004 defined its ICER threshold at £20,000 per quality added life year 
(QALY), rising to a maximum of £30,000/QALY if specific exceptional circumstances 
applied. Nevertheless, this basic threshold range has remained unaltered and has 
not accounted for inflation, the rate at which the general level of prices for goods 
and services rises. This research aims to model how the NICE threshold would vary 
if it fluctuated in line with the UK inflation rate and what effect this could have on 
appraisal outcomes. MethOds: Annual UK historical and forecast inflation rates 
were sourced from rateinflation.com (2004- 2016), upon which the effects on the 
NICE thresholds were modelled. Base-case ICERs were extracted from NICE Single 
Technology Appraisal (STA) reports for oncologics from 2006-July 2014. Results: 
Annual UK inflation rates varied from 0.4% to 4.5% (average 2.4%). Cumulatively, this 
amounts to a 29% decrease in the value of UK currency in this period. This means 
that in 2016 the NICE thresholds would need to rise to £26,100 and £39,150 to be 
monetarily equivalent to their 2004 levels. 60 NICE STA reports with base-case ICERs 
were extracted (average $68,636/QALY, range: US$5,390-234,009/QALY), 27 of which 
(45%) were not recommended. 35% (23/65) had a base-case ICER below £30,000 but 
this increased to 52% (34/65) if the £39,150 threshold is utilised. cOnclusiOns: 
The cumulative effects of inflation over time can be substantial. HTA bodies are 
artificially raising this threshold by not accounting for this fall in the currency 
purchasing power over time. ICER thresholds should be subject to periodic updat-
ing to account for inflation.
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analysis of the RelationshiP between Patient-RePoRted outcomes 
(PRos) and clinical outcomes in metastatic castRation-Resistant 
PRostate canceR (mcRPc) Patients without PRioR chemotheRaPy
Traina S1, Li T1, Johnson K1, Ho KF2, Molina A3, Cella D4
1Janssen Research & Development, Raritan, NJ, USA, 2STAT-TU Inc., Toronto, ON, Canada, 
3Janssen Research & Development, Menlo Park, CA, USA, 4Northwestern University Feinberg 
School of Medicine, Chicago, IL, USA
Objectives: PROs are used in prostate cancer clinical trials to measure thera-
peutic impact. We explored the temporal relationship between changes in PROs 
